Atıf İçin Kopyala
KARAKULAK U. N., KAYA E. B., ŞAHİNER M. L., ÖZER N., YORGUN H., Oto A., ...Daha Fazla
EUROPEAN JOURNAL OF THERAPEUTICS, cilt.27, sa.2, ss.149-157, 2021 (ESCI)
-
Yayın Türü:
Makale / Tam Makale
-
Cilt numarası:
27
Sayı:
2
-
Basım Tarihi:
2021
-
Doi Numarası:
10.5152/eurjther.2021.20128
-
Dergi Adı:
EUROPEAN JOURNAL OF THERAPEUTICS
-
Derginin Tarandığı İndeksler:
Emerging Sources Citation Index (ESCI), TR DİZİN (ULAKBİM)
-
Sayfa Sayıları:
ss.149-157
-
Anahtar Kelimeler:
Drug eluting stent, everolimus, coronary artery disease, ANTIPLATELET THERAPY, CLINICAL-EVALUATION, FOLLOW-UP, OUTCOMES, DISEASE, HYPERTENSION, PREVALENCE, AWARENESS, APPROVAL, TURKEY
-
Hacettepe Üniversitesi Adresli:
Evet
Özet
Objective: Drug eluting stents have become an important component in percutaneous treatment of patients with symptomatic coronary artery disease. The population in the previous drug eluting stent studies has very risk profile, and therefore not reflects real-world information. Moreover, there are limited data to evaluate risk factors and predictors of intended outcomes. In this study, everolimus eluting stent (XIENCE V) implantations and follow-up results in patients with coronary artery disease were evaluated.